Tamarix Pharma

Company Overview

Snapshot

Founded in July 2020 by Isaac (Tzachy) Tal, Tamarix Pharma operates with 1–10 employees. The company secured its seed funding in January 2021, attracting investment from Israel Biotech Fund and Xenia Venture Capital.

Business overview

Tamarix Pharma is an early-stage biotech company focused on developing novel technologies to restore physiological balance in apoptosis-related diseases. The company's core products, VBIT-4 and VBIT-12, are small molecules designed to target VDAC1 oligomerization, a key mitochondrial process. This unique mechanism of action aims to treat various acute and chronic conditions resulting from apoptotic cell death. Tamarix Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, and targets the life sciences and pharmaceutical industries.

Company Intelligence Q&A

What is Tamarix Pharma's primary focus?

Tamarix Pharma is an early-stage biotech company focused on developing novel technologies that restore physiological balance in apoptosis-related diseases.

When was Tamarix Pharma founded?

Tamarix Pharma was founded in July 2020.

What are Tamarix Pharma's lead assets?

Tamarix Pharma's lead assets are VBIT-4 and VBIT-12, which are small molecules targeting VDAC1 oligomerization.

Which investors participated in Tamarix Pharma's seed funding round?

In January 2021, Tamarix Pharma received seed funding from Israel Biotech Fund and Xenia Venture Capital.

What is the current status of Tamarix Pharma?

Tamarix Pharma is currently non-active, having ceased operations in May 2023.